Cancer Research and Treatment

Original Articles

Sarcoma

Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study: Xin Liu, Chengcheng Gong, Jieyun Zhang, Wanjing Feng, Yanjing Guo, Youzhou Sang, Chunmeng Wang, Yong Chen, Jian Wang, Lin Yu, Xiaowei Zhang, Zhiguo Luo; Cancer Res Treat. 2023;55(3):1001-1010. Published online March 3, 2023; DOI: https://doi.org/10.4143/crt.2022.894

Abstract PDF Supplementary Material PubReader ePub

Purpose
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy that occurs primarily in children and adolescents. The clinical and pathological features of IMT in adult patients are not well understood.
Materials and Methods
We retrospectively searched for records of adult patients with IMT at Fudan University Shanghai Cancer Center from 2006 to 2021. Clinicopathological data, treatments, and outcomes were collected and analyzed.
Results
Thirty adult patients with IMT, mostly women (60.0%), were included. The median age of the patients was 38 (21-77). The most common primary site was abdominopelvic region (53.3%), followed by lungs (20.0%). Seven patients had an abdominal epithelioid inflammatory myofibroblast sarcoma (EIMS). The positivity rate of anaplastic lymphoma kinase (ALK) was 81.5% (22/27). Sixteen patients with advanced ALK-positive disease received crizotinib, with an objective response rate (ORR) of 81.3% and a disease control rate of 87.5%. The median progression-free survival was 20.8 months. EIMS was associated with more aggressive behavior; however, the prognosis was similar to that of non-EIMS patients after treatment with an ALK inhibitor. At a median follow-up time of 30 months (95% confidence interval [CI], 13.6 to 46.4), the 5-year overall survival was 77% (95% CI, 66 to 88) in all patients.
Conclusion
Adult IMTs appeared more aggressive, with a higher incidence of recurrence and metastases, and patients with EIMS had more aggressive cases. Treatment with ALK inhibitors resulted in a high ORR and a durable response, which suggested that ALK inhibitors could be used as a first-line treatment option in adult patients with ALK-positive advanced IMT.

Citations

Citations to this article as recorded by

Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
Xiaoyan Si, Shafei Wu, Ruie Feng, Mengzhao Wang, Hanping Wang, Xiaotong Zhang, Li Zhang, Kaifeng Xu
Thoracic Cancer.2025;[Epub] CrossRef
Case report: Intra-abdominal inflammatory myofibroblastic tumor with mucinous features: a case of rapid recurrence and dissemination post-surgery
Xingchen Li, Jie Li, Chunxiao Liang, Qing Zou
Frontiers in Oncology.2025;[Epub] CrossRef
Clinical diagnosis and treatment of abdominal inflammatory myofibroblastic tumors
Qiang Zhang, Zhi-wei Zhang, Jing Fan, Zhuo-Ma Ji, Chun-Yan Wang, Feng Liu
Discover Oncology.2025;[Epub] CrossRef
Therapeutic strategy and prognostic analysis of inflammatory myofibroblastic tumor in the head and neck: a retrospective study
Feng Liu, Yanchao Qin, Zhiwei Zhang, Mengru Li, Bowei Feng, Wei Ding, Shubin Dong
PeerJ.2025; 13: e19315. CrossRef
Inflammatory myofibroblastic tumor of the adrenal gland: A case report
Jiyao Yang, Hongjin Shi, Haifeng Wang, Yidao Liu
Urology Case Reports.2024; 55: 102763. CrossRef
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations
Francisco Cristóbal Muñoz-Casares, Javier Martín-Broto, Pedro Cascales-Campos, Juan Torres-Melero, Irene López-Rojo, José Gómez-Barbadillo, Luis González-Bayón, Ana Sebio, César Serrano, Sara Carvalhal, Joaquim Abreu de Souza, Alexandre Souza, Guillermo F
Cancers.2024; 16(15): 2646. CrossRef
Thoracic epithelioid inflammatory myofibroblastic sarcoma: a rare and aggressive disease with case report and literature review
Linke Yang, Pei Li, Runze Liu, Baomin Feng, Huiqing Mao, Xiaoyong Tang, Guangjian Yang
Discover Oncology.2024;[Epub] CrossRef
Metastasized inflammatory myofibroblastic tumor of uterine origin
Thomas Bartl, Michael Deavers, Ryan Blair Kieser, Pedro T Ramirez
International Journal of Gynecological Cancer.2024; 34(10): 1643. CrossRef
Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib—a case report
Rafał Becht, Kajetan Kiełbowski, Justyna Żychowska, Wojciech Poncyljusz, Aleksandra Łanocha, Katarzyna Kozak, Ewa Gabrysz-Trybek, Paweł Domagała
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Rare giant epithelioid inflammatory myofibroblastic sarcoma of the abdominal cavity in a child: a case report and review of the literature
Jinzhou Li, Haixing Su, Sheng Zhang, Xianyun Chen, Chongzhi Hou, Tao Cheng
Frontiers in Oncology.2024;[Epub] CrossRef
Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment
PAULINA CHMIEL, ALEKSANDRA SłOWIKOWSKA, ŁUKASZ BANASZEK, ANNA SZUMERA-CIEćKIEWICZ, BARTłOMIEJ SZOSTAKOWSKI, MATEUSZ J. SPAłEK, TOMASZ ŚWITAJ, PIOTR RUTKOWSKI, ANNA M. CZARNECKA
Oncology Research.2024; 32(7): 1141. CrossRef

3,994 View
144 Download
9 Web of Science
11 Crossref

Preclinical Study of Novel Curcumin Analogue SSC-5 Using Orthotopic Tumor Xenograft Model for Esophageal Squamous Cell Carcinoma: Lai Nar Tung, Senchuan Song, Kin Tak Chan, Mei Yuk Choi, Ho Yu Lam, Chung Man Chan, Zhiyong Chen, Hector K. Wang, Hoi Ting Leung, Simon Law, Yanmin Huang, Huacan Song, Nikki P. Lee; Cancer Res Treat. 2018;50(4):1362-1377. Published online January 24, 2018; DOI: https://doi.org/10.4143/crt.2017.353

Abstract PDF PubReader ePub

Purpose
Tumor xenograft model is an indispensable animal cancer model. In esophageal squamous cell carcinoma (ESCC) research, orthotopic tumor xenograft model establishes tumor xenograft in the animal esophagus, which allows the study of tumorigenesis in its native microenvironment.
Materials and Methods
In this study,we described two simple and reproducible methods to develop tumor xenograft at the cervical or the abdominal esophagus in nude mice by direct injection of ESCC cells in the esophageal wall.
Results
In comparing these two methods, the cervical one presented with more clinically relevant features, i.e., esophageal stricture, body weight loss and poor survival. In addition, the derived tumor xenografts accompanied a rapid growth rate and a high tendency to invade into the surrounding structures. This model was subsequently used to study the anti-tumor effect of curcumin, which is known for its potential therapeutic effects in various diseases including cancers, and its analogue SSC-5. SSC-5 was selected among the eight newly synthesized curcumin analogues based on its superior anti-tumor effect demonstrated in an MTT cell proliferation assay and its effects on apoptosis induction and cell cycle arrest in cultured ESCC cells. Treatment of orthotopic tumor-bearing mice with SSC-5 resulted in an inhibition in tumor growth and invasion.
Conclusion
Taken together, we have established a clinically relevant orthotopic tumor xenograft model that can serve as a preclinical tool for screening new anti-tumor compounds, e.g., SSC-5, in ESCC.

Citations

Citations to this article as recorded by

Unveiling Another Dimension: Advanced Visualization of Cancer Invasion and Metastasis via Micro-CT Imaging
Sergey Tkachev, Vladimir Brosalov, Oleg Kit, Alexey Maksimov, Anna Goncharova, Evgeniy Sadyrin, Alexandra Dalina, Elena Popova, Anton Osipenko, Mark Voloshin, Nikolay Karnaukhov, Peter Timashev
Cancers.2025; 17(7): 1139. CrossRef
Network pharmacology and molecular docking reveal the mechanisms of curcumin activity against esophageal squamous cell carcinoma
Jian Wang, Zhilong Zhang, Qian Li, Zilong Hu, Yuan Chen, Hao Chen, Wei Cai, Qiancheng Du, Peng Zhang, Dian Xiong, Shugao Ye
Frontiers in Pharmacology.2024;[Epub] CrossRef
Curcumin: recent updates on gastrointestinal cancers
Muhammad Imran, Farhan Saeed, Suliman A. Alsagaby, Ali Imran, Ishtiaque Ahmad, Ahmad H. El Ghorab, Mohamed A. Abdelgawad, Tahira Batool Qaisrani, Tahir Mehmood, Maryam Umar, Muhammad Arslan Mumtaz, Arfaa Sajid, Qaisar Manzoor, Muzzamal Hussain, Waleed Al
CyTA - Journal of Food.2023; 21(1): 502. CrossRef
The anticancer effects of curcumin and clinical research progress on its effects on esophageal cancer
Shimeng Wang, Xinliang Gao, Jialin Li, Shixiong Wei, Yifeng Shao, Yipeng Yin, Duo Zhang, Mingbo Tang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review
Korosh Morshedi, Sarina Borran, Mohammad Saeid Ebrahimi, Mohammad Jaber Masoud khooy, Zeynab Sadat Seyedi, Atefeh Amiri, Mohammad Abbasi‐Kolli, Maryam Fallah, Haroon Khan, Amirhossein Sahebkar, Hamed Mirzaei
Phytotherapy Research.2021; 35(9): 4834. CrossRef
Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
Shoh Yajima, Kotaro Sugawara, Miwako Iwai, Minoru Tanaka, Yasuyuki Seto, Tomoki Todo
Molecular Therapy - Oncolytics.2021; 23: 402. CrossRef
Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status
AmirReza Hesari, Mitra Azizian, Alireza Sheikhi, Abolfazl Nesaei, Shahin Sanaei, Nazanin Mahinparvar, Maryam Derakhshani, Pegah Hedayt, Faezeh Ghasemi, Hamed Mirzaei
International Journal of Cancer.2019; 144(6): 1215. CrossRef
Latest in Vitro and in Vivo Assay, Clinical Trials and Patents in Cancer Treatment using Curcumin: A Literature Review
Kevin Doello, Raúl Ortiz, Pablo J. Alvarez, Consolación Melguizo, Laura Cabeza, José Prados
Nutrition and Cancer.2018; 70(4): 569. CrossRef
Tumor xenograft animal models for esophageal squamous cell carcinoma
Nikki P. Lee, Chung Man Chan, Lai Nar Tung, Hector K. Wang, Simon Law
Journal of Biomedical Science.2018;[Epub] CrossRef

10,679 View
266 Download
12 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search